Duyen Tran1
Stephen Myers2
Courtney McGowan2,3
Darren Henstridge2
Rajaraman Eri2Sabrina Sonda2†
Vanni Caruso1,4*†- 1School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
- 2School of Health Science, College of Health and Medicine, University of Tasmania, Launceston, TAS, Australia
- 3Sport Performance Optimization Research Team, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, TAS, Australia
- 4Institute for Research on Pain, Istituto di Formazione e Ricerca in Scienze Algologiche (ISAL) Foundation, Rimini, Italy
Metabolic dysfunction, dysregulated differentiation, and atrophy of skeletal muscle occur as part of a cluster of abnormalities associated with the development of Type 2 diabetes mellitus (T2DM). Recent interest has turned to the attention of the role of 1-deoxysphingolipids (1-DSL), atypical class of sphingolipids which are found significantly elevated in patients diagnosed with T2DM but also in the asymptomatic population who later develop T2DM. In vitro studies demonstrated that 1-DSL have cytotoxic properties and compromise the secretion of insulin from pancreatic beta cells. However, the role of 1-DSL on the functionality of skeletal muscle cells in the pathophysiology of T2DM still remains unclear. This study aimed to investigate whether 1-DSL are cytotoxic and disrupt the cellular processes of skeletal muscle precursors (myoblasts) and differentiated cells (myotubes) by performing a battery of in vitro assays including cell viability adenosine triphosphate assay, migration assay, myoblast fusion assay, glucose uptake assay, and immunocytochemistry. Our results demonstrated that 1-DSL significantly reduced the viability of myoblasts in a concentration and time-dependent manner, and induced apoptosis as well as cellular necrosis. Importantly, myoblasts were more sensitive to the cytotoxic effects induced by 1-DSL rather than by saturated fatty acids, such as palmitate, which are critical mediators of skeletal muscle dysfunction in T2DM. Additionally, 1-DSL significantly reduced the migration ability of myoblasts and the differentiation process of myoblasts into myotubes. 1-DSL also triggered autophagy in myoblasts and significantly reduced insulin-stimulated glucose uptake in myotubes. These findings demonstrate that 1-DSL directly compromise the functionality of skeletal muscle cells and suggest that increased levels of 1-DSL observed during the development of T2DM are likely to contribute to the pathophysiology of muscle dysfunction detected in this disease.
Introduction
1-deoxysphingolipids (1-DSL) are a class of atypical sphingolipids found significantly elevated in plasma of individuals with impaired fasting glucose, metabolic syndrome (MetS) and T2DM (1, 2). Interestingly, recent clinical studies demonstrated that plasma 1-DSL are also significantly elevated in non-diabetic individuals who later develop T2DM (3). In contrast, these atypical lipids are not elevated in patients with diabetes type 1 (T1DM) (4). This suggests that 1-DSL could be considered early predictors of T2DM independently of the levels of glycated haemoglobin and MetS in general population (3, 5). Recent studies revealed that these atypical lipids were found significantly elevated in obese and T2DM patients compared to athletes and lean individuals, and that their accumulation appeared to cause insulin resistance in vitro (5). However, the underlying molecular mechanisms leading to development of T2DM in patients with elevated atypical sphingolipids have not been fully elucidated.
The first step in de novo sphingolipid synthesis occurs in the endoplasmic reticulum (ER) where the enzyme serine palmitoyltransferase (SPT) catalyses the condensation of serine and palmitoyl Co-A to form sphinganine (SA) which is then metabolised to ceramide and complex sphingolipids (sphingomyelins, glycosphingolipids) (6). On the other hand, when alanine is used over serine, SPT sintethises the atypical sphingolipids 1-DSL. This class of sphingolipids lacks the C1-OH group of canonical sphingolipids which make them resistant to normal sphingolipid catabolism thus resulting in the accumulation of 1-DSL inside cells and tissues (7). Recent in vitro studies have demonstrated accumulation of 1-DSL promote death of pancreatic beta-cells and interfere with insulin secretion (8) and may be involved in the mechanisms of insulin resistance (5). Another clinical study showed that 1-DSL levels are elevated in the early stages of diabetic neuropathy, although this elevation did not correlate with the clinical course of the disease (9).
Deterioration of skeletal muscle mass is a hallmark of patients with T2DM (10). A reduction in skeletal muscle’s ability to respond to insulin and the subsequent development of insulin resistance are key events in the establishment of high blood glucose levels and impaired glycaemic control. In addition to these metabolic dysfunctions, muscle loss or atrophy is associated with diminished strength, quality of life, and early mortality (11, 12). T2DM-generated muscle atrophy is initiated by dysfunctions in the activity of myogenic progenitor cells, so-called myoblasts (13–15). Specifically, proliferation, migration, and differentiation of myoblasts, which are vital for the maintenance of skeletal muscle integrity, are reduced during T2DM (16, 17). While muscle dysfunction and atrophy coincide with the development of T2DM, the exact relationship between T2DM and the reduced functionality of myoblasts remains largely unexplored.
Given the cytotoxic properties associated with atypical lipids, the aim of this study was to investigate whether 1-DSL compromises the functionality of skeletal myoblasts and their differentiation into mature myotubes thus contributing to the pathophysiology of T2DM.
Materials and Methods
Mammalian Cell Culture
Immortalised mouse C2C12 myoblast cell line (ATCC, CRL-1772, USA) was cultured in a complete medium comprising high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) – (Sigma, D6429, USA), 10% Fetal Bovine Serum (FBS) (Thermo Fisher Scientific, 10099158, USA), and 1X penicillin-streptomycin (Thermo Fisher Scientific, 10378016, USA) at 37°C, 5% CO2, and saturating humidity. The cells were passaged once a week before reaching confluence using Trypsin – EDTA solution (Sigma, T4049, USA).
To induce myoblast differentiation into myotubes, the complete medium was changed to a differentiation medium of DMEM with 2% horse serum (Thermo Fisher Scientific, 260500, USA) and 1X penicillin-streptomycin for 5 days. Lipid treatments included either 1-deoxysphinganine (Avanti Polar Lipids, 860493P, USA) or the control non-toxic - sphinganine (Avanti Polar Lipids, 860498P, USA), or the control toxic - palmitic acid (Sigma, P0500, USA) which causes insulin resistance in skeletal muscle cells (18). Lipids were dissolved in absolute ethanol to obtain a stock concentration of 1 mM. Fatty acid-free - bovine serum albumin (Sigma, A6003, USA) was used as a lipid carrier and added to the complete medium at the same molar concentration as the lipids. The working concentrations for lipids were prepared by diluting lipid stock solutions in a complete medium or differentiation medium according to the relevant assays.
Cell Viability Assay
C2C12 cells were seeded into 96-well plates (2x104 cells/well) and lipids at concentrations of 0.5 µM, 1 µM, and 3 µM, were added when the cells reached 100% confluency, as described in the figure legends. The numbers of live and dead cells were quantified by staining with Trypan Blue dye (Life Technologies, 5250061, USA) and manual counting was performed using a Neubauer chamber (Blau Brand, 717810, Germany). Alive cells as indicated by no Trypan blue staining were counted under a microscope and our read-out normalised to this number.
Cell viability was also quantified by Thiazolyl Blue Tetrazolium Bromide (MTT) assay. C2C12 cells (2x104 cells/well) were cultivated in 96 well plates and treated with the lipids as described in the figure legends. After the treatment period, 10 μL of 5 mg/mL MTT (Sigma, M5655, USA) was dissolved in PBS and was added to each well, and incubated for 2 hours at 37°C. After aspirating the supernatant, formazan crystals were dissolved in 100 µl of DMSO and quantified by measuring the absorbance at 570 nm and reference at 670 nm using the Infinite 200 Pro microplate reader (Tecan, 396235, Switzerland).
ATP Assay
Intracellular Adenosine Triphosphate (ATP) levels at different time points were quantified using the CellTiter-Glo Luminescent Viability Assay (Promega, G7570, USA), following the manufacturers’ instructions. Luminescence was recorded over an integration period of 0.25 to 1 second using the Infinite 200 Pro microplate reader. ATP levels for each cell were calculated by normalizing the luminescence levels to the number of live cells After lipid treatment, wells were washed with 1X PBS, then 50 μL of Trypsin was added to the wells and incubated for 10 min. Trypsin reaction was stopped by adding 60 μL fresh 10% FBS DMEM (total volume = 110 μL). 10 μL of cell suspension was mixed with 10 μL of Trypan blue. Alive cells as indicated by no Trypan blue staining were counted under a microscope and our read-out normalised to this number. Data = luminescence RLU/number of live cells.
Immunocytochemistry
Cells (2x104 cells/well) were grown in Nunc Lab-Tek 8-chamber slides (Sigma, C7182, USA) and treated with the lipids as described in the figure legends. Cells were then fixed with 4% formaldehyde (Life Technologies, FB002, USA), permeabilised with 0.2% Triton X-100 (Sigma, T9284, USA), and incubated in primary antibodies diluted in blocking solution (2% bovine serum albumin (BSA) (Sigma, A6003, USA). Primary antibodies used were rabbit anti-cleaved caspase-3 (D175) (1:400, Cell Signalling Technology, 9661S, USA), rabbit anti-p62/SQSTM1 (1:500, Cell Signaling Technology, 4108, USA) subsequently incubated with secondary antibodies Alexa Fluor 594 goat anti-rabbit IgG (H+L) (1:500, Invitrogen, A-11037, USA). F-actin was visualised with Phalloidin-FITC (1:32, Sigma, P5282, USA) and nuclei with DAPI contained in Prolong mounting solution (Life Technologies, P36941, USA). Microscopy analyses were performed on a wide-field EVOS M5000 Cell Imaging microscope (Thermo Fisher, AMF5000, USA). Quantification of labelled cells was performed in at least 5 randomly selected high-power fields (60X magnification) per slide using the ImageJ Software (version v1.52a, National Institutes of Health, USA).
Migration Assay
Myoblast migration assay was carried out as previously described (19, 20). Briefly, myoblasts (5 x 104 cells/well) were seeded in 24-well-plates until reaching confluency and then incubated for 24 hours with DMEM containing 1% FBS. The cell monolayer was scratched with a pipette tip to obtain an acellular area in the middle of the well. Lipids were then added to the cells in a fresh medium with 1% FBS. Scratch width was measured using an EVOS M5000 Cell Imaging microscope (Thermo Fisher, AMF5000, USA). Myoblast migration at different incubation times was calculated as the percentage of scratch width over the initial scratch width.
Myoblast Fusion Assay
Myoblast’s differentiation was induced for 5 days with or without lipids. Cells were then fixed in 100% cold methanol, and myotubes stained as previously described (21–23), with minor modifications. Briefly, cells were stained with May-Grunwald solution (Abcam, 150670, UK) for 15 minutes followed by Giemsa staining solution (Abcam, 150670, UK) for 30 minutes. Cells were visualized with the EVOS M5000 Cell Imaging microscope (Thermo Fisher, AMF5000, USA). Myotubes containing at least 3 nuclei were counted in 5 randomly selected regions per well using ImageJ software (version v1.52a, National Institutes of Health, USA).
Glucose Uptake Assay
Glucose uptake was assessed in myotubes using the Glucose Uptake-Glo Assay (Promega, J1341, USA) following the manufacturer’s instructions. After three days of differentiation, myotubes were treated with either a control medium (no lipids) or medium with 0.5 μM/3 μM lipids, for two additional days. On the last day of treatment, serum was not added to the differentiation medium. Cells were then treated with or without 100 nM insulin for 2 hours at 37 °C, followed by the addition of 100 μM 2-deoxyglucose for 10 min at 37 °C. Glucose uptake was quantified recording luminescence with 0.3 to 1 second integration time using the Infinite 200 Pro microplate reader. Glucose uptake levels were then normalized to the number of live cells. After lipid treatment, wells were washed with 1X PBS, then 50 μL of Trypsin was added to the wells and incubated for 10 min. Trypsin reaction was stopped by adding 60 μL fresh 10% FBS DMEM (total volume = 110 μL). 10 μL of cell suspension was mixed with 10 μL of Trypan blue. Alive cells as indicated by no Trypan blue staining were counted under a microscope and our read-out normalised to this number. Data = luminescence RLU/number of live cells.
Statistical Analysis
Each experiment was the average of three independent experiments. All treatments and time-points were performed in triplicates. All statistical analyses were completed using GraphPad Prism version 8.3.0 Statistics for Windows (GraphPad Software, San Diego, California USA). The effects of 1-DSA on cellular viability, metabolic activity, energy (ATP) production levels, migration, and the fusion of myoblasts were analysed by one-way ANOVA with 1-DSA treatment as factors. The effect of 1-DSA on glucose uptake of myotubes was analysed by two-way ANOVA with insulin effect and 1-DSA effect as factors. ANOVA results were then followed by a post hoc analysis using Tukey’s Honest Significant Difference test as appropriate. The effects of 1-DSA on inducing apoptosis, necrosis, and autophagy on myoblasts were analysed by two-tailed Student’s t-test. Data are presented as mean ± Standard Error of Mean (SEM). The results were considered statistically significant when p < 0.05.
Results
1-DSA Treatment Reduces the Viability of Myoblasts
We investigated whether incubation with 1-DSL is directly toxic to C2C12 myoblasts, the most commonly used mouse skeletal muscle cell line (24, 25). Myoblasts were treated with low micromolar concentrations (0.5 µM, 1 µM, and 3 µM) of either the 1-DSL 1-deoxysphinganine (1-DSA) or the control sphinganine (SA). Incubation with 1-DSA significantly lowered the number of living cells in a concentration-dependent manner, as assessed by trypan blue exclusion assay (Figure 1A) and MTT assay (Figure 1B). There was no significant difference between the control SA groups at all the concentrations tested.
Figure 1 1-DSA reduce viable cell numbers in a concentration and time-dependent manner. (A) Cell viability of C2C12 myoblasts treated at 100% confluence with SA or 1-DSA at the selected concentrations and incubated for 24 hours and tested by trypan blue exclusion assay. SA groups were used as control. (B) Cell viability of C2C12 myoblasts treated with the designated SA or 1-DSA concentrations for 24 hours by MTT assay. (C) Cell viability of myoblasts treated with 3 μM SA or 3 μM 1-DSA at the indicated time points up to 24 hours by trypan blue exclusion assay. (D) Cell viability of C2C12 myoblasts treated with 3 μM SA or 3 μM 1-DSA at the indicated time points up to 24 hours by MTT assay. (E) Bright-field images showing C2C12 myoblast morphology treated at 100% confluence with 3 μM 1-DSA and 3 μM SA at indicated time points. (F) Cell viability of C2C12 myoblasts treated at 100% confluence with SA or 1-DSA at 1 µM and 3 µM and incubated for 24 hours, by trypan blue exclusion assay. Data are presented as mean ± SEM (n=3). *p < 0.05, SA vs. 1-DSA in (A–D, F); one-way ANOVA followed by post hoc tests. (G) Cell viability of C2C12 myoblasts treated at 100% confluence with control or palmitic acid at 200 µM and 500 µM and incubated for 24 hours, by trypan blue exclusion assay. Data are presented as mean ± SEM (n=3). *p < 0.05, control versus palmitic acid; one-way ANOVA followed by post hoc tests. (H) Representative cellular morphological images under the effect of 1-DSA (1 μM and 3 μM, respectively) and palmitic acid (200 μM and 500 μM, respectively) after 24 hour-incubation. Scale bars: 100 μm.
We then tested whether 1-DSA significantly reduced the number of live cells in a time-dependent manner. We measured cell viability over time upon incubation with 3 μM 1-DSA, a concentration that greatly reduced the number of live cells after 24 hours of treatment (See Figures 1A, B). Three micromoles of 1-DSA did not affect cell viability after 4 hrs of incubation, but significantly reduced the number of viable cells over the 24-hour-period, as determined by trypan blue exclusion assay (Figure 1C) and MTT assay (Figure 1D), which suggested that 1-DSL suppressed myoblast proliferation. A significant reduction in the number of live cells was accompanied by morphological alterations of C2C12 cells, including rounding up and detachment from the well surface (Figure 1E).
Lipid-induced toxicity has been demonstrated in muscle cells in the presence of saturated fatty acids (26). This lipotoxicity has the potential to induce insulin resistance in muscle cells (27, 28), and thus contribute to the pathophysiology of diabetes. We compared the lipotoxicity of the saturated fatty acid palmitic acid with 1-DSA. Treatment with 1-DSA (1 and 3 µM) significantly reduced the number of viable cells at concentrations significantly lower than palmitic acid (200 and 500 µM) (Figures 1F, G). Additionally, 1-DSA induced more cell rounding and detachment from the surface of the cell-culture flask, compared to the palmitic acid treatment (Figure 1H). This demonstrates that 1-DSA is much more cytotoxic to myoblasts than palmitic acid.
1-DSA Induce Necrosis, Apoptosis, and Autophagy and Raise ATP Levels in C2C12 Myoblasts
The reduction in live cell number observed upon 1-DSA treatment may be attributed to either reduced myoblast proliferation or increased cell death. The morphological changes described in (Figures 1E, H) suggest that incubation with the lipids induces cell death. This is in line with previous investigations in which an increase in ATP levels could be considered as pre-requisite of apoptotic processes (29, 30). This was further confirmed by quantification of dead cell numbers by trypan blue staining, showing that 3 μM of 1-DSA increased the number of trypan blue positive myoblasts (Figures 2A, B). Trypan blue staining relies on the loss of membrane integrity and is a strong indicator of cellular necrosis (31).
Figure 2 1-DSA induced necrosis, apoptosis, and autophagy in C2C12 cells. (A) Representative image of trypan blue stained myoblasts after 16-hour-treatment with either control 3 μM SA or 3 μM 1-DSA. The arrows depict positive necrotic stained cells. Scale bars, 350 μm. (B) Quantification of C2C12 necrotic dark blue dead cell numbers. (C) Quantification of positive stained apoptotic cells. (D) Representative images of C2C12 myoblast after 16-hour treatment with either control 3 μM SA or 3 μM 1-DSA, as shown by immunostaining with apoptotic marker Cleaved Caspase-3 (red), FITC-phalloidin (green), and DAPI (blue). Arrows indicate cleaved-caspase 3-positive cells. Scale bars, 50 μm. (E) Quantification of cellular ATP levels in C2C12 myoblasts with either 3 μM of SA or 1-DSA treatment at indicated time points. Data are presented as mean ± SEM (n=3). *p < 0.05, SA vs. 1-DSA; one-way ANOVA followed by post hoc tests. (F) 1-DSA induced autophagy as shown by immunostaining with autophagic marker P62/SQSTM1 (red), FITC-phalloidin (green), and DAPI (blue). Arrows indicate P62/SQSTM1-positive cells. Scale bars, 50 μm. (G) Quantification of positive stained autophagic cells. Data in (B, D, G) are presented as mean ± SEM (n=3); *p < 0.05, SA vs. 1-DSA; unpaired student’s t-test.
Immuno-staining for the apoptotic marker cleaved caspase-3 revealed that treatment with 3 μM of 1-DSA significantly induced apoptosis in C2C12 myoblasts (Figure 2C). Cleaved caspase-3 positive cells showed nuclear condensation and cell shrinkage, characteristic features of the apoptotic process (Figure 2D). To further investigate the induction of apoptosis upon 1-DSA incubation, we quantified cellular ATP content, as increased ATP is required to support the activity of hydrolytic enzymes, chromatin condensation, and formation of membrane-enclosed vesicles observed during apoptotic cell death (29). ATP levels were higher in 1-DSA treated cells at all the time points analysed (Figure 2E), further supporting that 1-DSA triggers apoptosis in C2C12 myoblasts.
Finally, we investigated the cellular processes underlying 1-DSA-mediated cytotoxicity. Autophagy is often associated with cell death (32, 33) and 1-DSA have recently been shown to increase the autophagic flux in embryonic fibroblasts and macrophages (34). Treatment with 3 μM of 1-DSA significantly increased the number of cells expressing the autophagic marker P62/SQSTM1 (Figures 2F, G), thus demonstrating that 1-DSA trigger autophagy in C2C12 myoblasts.
1-DSA Inhibit the Migration of C2C12 Myoblasts
Myoblast migration is critical for muscle integrity and regeneration as cell migration is the first step for myoblast differentiation (35, 36). Both myoblast migration and differentiation are impaired in T2DM (14, 17, 37–40), thus, we tested whether incubation with 1-DSA reduces the migration ability of C2C12 myoblasts. We incubated C2C12 myoblasts with 0.5 μM and 1 μM of 1-DSA, concentrations that induced only a minor decrease in the number of live cells and thus minimising the confounding element of cell death in our analysis. Our results showed that 1-DSA significantly reduced migration of myoblasts in a concentration-dependent and time-dependent manner, as measured by a wound-healing assay. (Figures 3A, B).
Figure 3 1-DSA significantly reduces the migration of muscle cells in a concentration and time-dependent manner, as tested by Wound-healing assay. (A) The wound-healing results are represented as the percentage of the initial wound area. Values are expressed as mean ± SEM (n = 3). *p < 0.05, SA vs. 1-DSA; one-way ANOVA followed by post hoc tests. (B) The representative wound-healing images of C2C12 myoblasts under the effect of either SA or 1-DSA were recorded by microscopy at the indicated time points. Scale bars: 350 μm.
1-DSA Impair C2C12 Myoblasts Fusion Into Myotubes
After demonstrating that 1-DSA treatment reduces myoblast migration, we further evaluated whether it also reduces myoblast fusion into myotubes, a key step for the differentiation of myoblasts into mature myofibers. Treatment with 0.5 μM and 1 μM 1-DSA over 5 days reduced the number of myotubes in a concentration-dependent manner compared to the control group SA, as detected by May-Grunwald Giemsa staining (Figures 4A, B). Concomitant with lowering the frequency of cell fusion into myotubes, 1-DSA treatment also altered the morphology of myotubes. Specifically, in control SA treated cells, myotubes were elongated and contained nuclei distributed along the longitudinal axis. Conversely, in 1-DSA treated cells, the majority of the myotubes were shorter than controls and contained multiple nuclei concentrated in the centre of the expanded cell body (Figure 4C).
Figure 4 1-DSA inhibits myogenic differentiation and impaired myotube formation. (A) Quantification of myotubes per well after 5 days of SA or 1-DSA treatment. Values are expressed as mean ± SEM (n = 3). *p < 0.05, SA vs. 1-DSA; one-way ANOVA followed by post hoc tests. (B) Representative May-Grunwald Giemsa staining images of day 0 and day 6 of differentiation of C2C12 cells. Scale bars: 350 μm. (C) Insets represented a higher magnification of 5-day-differentiated myotubes treated with either 1 μM SA or 1-DSA. White arrows depict myotubes. Dotted lines cover the shape of myotubes. Scale bars: 50 μm.
1-DSA Impair Insulin-Stimulated Glucose Uptake in C2C12 Myotubes
Glucose intolerance is a characteristic feature of T2DM, where insulin-responsive tissues like skeletal muscle lose their ability to be stimulated by insulin and uptake glucose, leading to compromised glucose homeostasis (10, 41). To test whether 1-DSA impairs glucose uptake in muscle cells, we differentiated C2C12 myoblast into myotubes for 3 days and quantified glucose uptake after 2 days exposure with SA or 1-DSA (treatment regimen depicted in Figure 5A). Incubation with 1-DSA for this length of time did not alter cell viability (Figure 5B). We found that incubation with 3 μM of 1-DSA reduced the overall amount of glucose taken up by the cells, both in the absence and presence of insulin (Figure 5C). This effect was concentration-dependent, as 0.5 μM 1-DSA did not change the level of glucose uptake compared with control treatments. The reduction of glucose uptake in the presence of 1-DSA may derive from a lower number of live cells present upon lipid incubation. This was confirmed by a reduction in viable cell number in 1-DSA treated samples assessed by Trypan blue and MTT assays, respectively (Figures 5B, D). Finally, we investigated the insulin response at a cellular level by quantifying glucose uptake normalised by the number of viable cells. 1-DSA treatment reduced the magnitude of the insulin response in C2C12 myotubes (Figure 5E), suggesting that the lipid perturbs glucose uptake in myotubes.
Figure 5 1-DSA induced insulin resistance by reducing glucose uptake in C2C12 5-day-differentiated-myotubes. (A) Model of C2C12 skeletal muscle differentiation and lipids SA or 1-DSA treatment for glucose uptake assay. SA was used as a control. (B) Cell viability of C2C12 myotubes treated with 3 μM SA or 1-DSA for 48 hours with/without insulin, as tested by trypan blue exclusion assay. No insulin groups were used as control. (C) Myotubes were treated with either 0 μM, 0.5 μM 1-DSA, or 3 μM SA/1-DSA with or without 100 nM insulin. Glucose uptake levels were determined with 2-DG by measuring luminescence, upon 48-hour- treatment with the lipids (D) Cell viability of C2C12 myotubes treated with 3 μM SA or 1-DSA for 48 hours with/without insulin, as tested by MTT assay. No insulin groups were used as control. (E) Quantification of glucose uptake level per live cell by normalizing luminescence to the number of live cells. Data are presented as a percentage of the control – SA/1-DSA no insulin group. Data correspond to the mean ± SEM (n = 3). *p < 0.05, no insulin vs. insulin; #p < 0.05, 1-DSA vs. SA; two-way ANOVA followed by post hoc tests.
Discussion
Over the last 20 years, T2DM rates around the globe have risen dramatically and its consequences represent a major public health concern (42). In T2DM, the metabolism and functionality of skeletal muscle, an organ that plays a major role in maintaining blood glucose homeostasis, are compromised, and these deteriorations contribute to the progression of the disease (43, 44). Therefore, identifying the molecular factors that compromise skeletal muscle before and during T2DM is key to counteract the disease.
The findings of this study demonstrate that in vitro incubation with 1-DSA cause functional impairments in C2C12 skeletal muscle precursor and differentiated cells and that these impairments are similar to the ones observed in vivo and in T2DM patients, which have increased levels of circulating 1-DSL.
It has to be clarified that in patients treated with anti-diabetic medications (insulin and/or other ipoglicemic drugs) and/or with fasting plasma glucose levels ≥ 7mmol/L, the average of circulating 1-DSL plasma levels was 0.09 μM/L (3). As in T2DM several physiological responses can be highly responsive to environmental factors such as drugs and diet, and contingent on the cellular context, we decided to use concentrations of 1-DSL ranging from 0.5 μM, 1 μM, to 3 μM in line with the current literature (8). The present study confirmed the previously reported cytotoxic effect of 1-DSL (45–48) and importantly identifies mechanisms that may contribute to the development of T2DM.
1-DSA Compromises the Functionality of Precursor Myoblasts and Differentiated Myotubes
Muscle atrophy is typified by a reduction in myofiber size and muscle mass, and the resulting loss of muscle function as well as strength are commonly observed in T2DM patients (14, 49). In the current study, we found that low micromolar concentrations (1 µM and 3 μM) of 1-DSA cells reduced the number of live cells in both precursor and differentiated C2C12 cells. These findings support the notion that even relatively low concentrations of 1-DSL detected in the blood of MetS (pre-diabetes) patients (50) and T2DM patients (3) may be harmful to skeletal muscle cells. The plasma levels of 1-DSL were previously reported to significantly elevate in T2DM patients compared to the healthy group (3, 50). In addition, we showed that 1-DSA cytotoxicity is time-dependent, as the magnitude of the deleterious effects increased after prolonged lipid exposure. This is in accordance with the concept that, as a result of their biological structure, 1-DSL are metabolized intracellularly very slowly compared to typical sphingolipids, thus leading to a gradual accumulation of 1-DSL inside the cells and consequent cellular dysfunction (45).
Fast replicating, sub-confluent myoblasts were particularly sensitive to 1-DSA exposure, leading to cell death (Supplementary Figure 1A), while the effect was less pronounced in slowly replicating confluent cells and differentiated myotubes (Supplementary Figure 1B). Further investigations are required to determine the mechanisms underlying the different sensitivity observed. However, the lower replication rate of the cells following confluency and differentiation may account for the lower lipotoxicity, as previously shown in insulin-producing beta cells (8).
Additional analyses on the characteristics of 1-DSA-induced toxicity revealed that incubation with the lipid inhibited myoblast migration and myoblast differentiation into myotubes. These processes are crucial to maintain muscle homeostasis. Specifically, myoblast migration and differentiation are key steps in myogenesis and regeneration (51–53). During the regeneration phase, myoblasts migrate to the affected areas and undergo terminal differentiation where they align and fuse into myotubes (54, 55). The biochemical features of C2C12 myoblast cell line represents a meaningful and effective examination tool to examine skeletal muscle metabolism and differentiation (1, 2). We investigated common myogenic markers (MyoG, FABP3), and we found that 1-DSL did not alter their gene expression (Supplementary Figure 2). Further studies in myoblast primary cell lines and in vivo investigations would offer a better understanding of the gene and protein expression levels of myogenic markers for a targeted therapeutic intervention in patients with elevated 1-DSL levels. Our results also suggest that 1-DSA could contribute to the impaired myoblast differentiation and regeneration observed in-vivo during T2DM, which leads to skeletal muscle wasting and loss that often accompanies insulin resistance (56). In addition, our results indicate that 1-DSA incubation compromise glucose uptake in differentiated muscle cells. This has important implications in understanding the pathophysiology of T2DM, as it suggests that the effect of 1-DSA in skeletal muscle cells may contribute to the increase in blood levels of glucose observed in the disease.
We also reported that 1-DSA are much more cytotoxic to myoblasts than palmitic acid, a well-known saturated fatty acid causing insulin resistance in muscle cells (26, 27, 57). The saturated fatty acid palmitate also has a harmful effect on the myotube size and morphology of C2C12 myotubes (58). Palmitate-stimulated insulin resistance in C2C12 myotubes is closely associated with the reduction on myotube numbers and reduced expression of health benefit myokine genes, which confirmed the negative effect of palmitate accumulation in myotubes (59). Therefore, these findings highlight the concept that both 1-DSL and saturated fatty acids are responsible for muscle cell lipotoxicity, which is a key contributing factor in the pathophysiology of T2DM (60–62).
Mechanisms of 1-DSA-Induced Lipotoxicity
Toxic effects induced by exposure to 1-DSA have been reported in different cell types, including insulin-producing β-cells (8), pancreatic acinar cells (63), and peripheral neurons (46, 48, 64), mouse embryonal fibroblasts (MEFs) (65), pig kidney epithelial cells and human prostate cancer cells (66). However, the underlying mechanisms of 1-DSA lipotoxicity have not been fully elucidated. Some studies reported that 1-DSA incubation damages the structure and functionality of intracellular organelles, including mitochondria (67), ER (65), and Golgi apparatus (34). Damaged or stressed organelles are normally degraded and recycled via the cellular process of autophagy (68). In addition to the previous study of Lauterbach et al., 1-DSA were recently found to alter cellular autophagy and to induce autophagosome accumulation in MEFs (34). Our data showed that exposure to 1-DSA increase autophagosomes formation in C2C12 myoblasts and altered autophagy activity is one of the major causes for a variety of skeleton muscle disorders (69). This is of special interest as dysfunction in the autophagic process is linked with the development of obesity and T2DM (13, 69). As plasma levels of 1-DSL are elevated in metabolic MetS and T2DM patients (2, 3), our findings suggest a potential involvement of 1-DSL in activating autophagosome in the context of the disease. Further investigations are required to elucidate the molecular mechanisms by which exposure to 1-DSA trigger autophagy. One possible cellular mediator for the observed phenotype is the generation of 1-deoxyceramide, a downstream metabolite of 1-DSA that accumulates in cells upon 1-DSA treatment in vitro (70). In addition, 1-deoxyceramide is highly enriched in vivo in visceral adipose tissue as well as in the serum of obese patients with T2DM (71). Ceramides are bioactive signalling molecules that counteract the activity of suppressors of autophagy, including Class I PI3K and AKT, via activation of PP2A (72). Ceramides have also been proven to alleviate IL-13-mediated inhibition of autophagy (73), which is believed to require the class I PI3K/AKT pathway (74). 1-DSA-derived 1-deoxyceramide may also contribute to the apoptotic death observed in skeletal muscle cells. In support of this hypothesis, ceramides can trigger caspases 3 and 7 and thus stimulate apoptosis (75). Ceramides can also alter the permeability of the outer membrane of mitochondria (75), by forming channels through the mitochondrial membrane (76), which is an critical step in the generation of apoptosis.
Conclusion
The findings of this study revealed that 1-DSA exerts cytotoxic effects in both myoblast progenitors and differentiated myotubes. Our study suggests that the risen levels of 1-DSL detected in T2DM patients may contribute to the diminished functionality of skeletal muscle tissue. Further studies are required to further validate our findings in primary muscle cells, human skeletal muscle organoids and mouse models. In addition, as circulating levels of 1-DSL can be modulated via dietary interventions (47, 63), additional investigations are warranted to test whether lowering 1-DSL may improve glycaemic control and then complement presently available therapies in preventing T2DM.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Author Contributions
This study was designed and coordinated by SS. Laboratory investigations and statistical analyses were performed by DT. The manuscript was designed and prepared by DT, VC, and SS. Manuscript was revised and commented by SM, RE, CM, and DH. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
The authors acknowledge Peter Traill, Melissa Aubrey at the School of Pharmacy and Pharmacology and Mandhi Allen, Clare Tanton, Georgina Dalgleish, Parisa Vahidi at the School of Health Science for methodological as well as technical assistance.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.772925/full#supplementary-material
Supplementary Figure 1 | 1-DSA reduce viable cell numbers in a concentration-dependent manner. (A) C2C12 cells were seeded at 5 x 103 cells/well. Cell viability of C2C12 myoblasts treated at sub-confluence with SA or 1-DSA at the selected concentrations and incubated for 24 h, as tested by MTT assay. SA groups were used as control. (B) C2C12 cells were seeded at 2 x 104 cells/well. Cell viability of C2C12 5-day-differentiated myotubes, included 24 h of SA or 1-DSA treatment at the selected concentrations, as tested by MTT assay. Data were presented as mean ± SEM (n=3). *p < 0.05, SA vs. 1-DSA; one-way ANOVA followed by post hoc tests.
Supplementary Figure 2 | Effect of 1-DSA on mRNA expression of myogenic markers. mRNA levels were normalized to EEF2 mRNA and presented as fold change.
Abbreviations
1-DSA, 1-deoxysphinganine; 1-DSL, 1-deoxysphingolipids; ATP, Adenosine Triphosphate; MTT, Thiazolyl Blue Tetrazolium Bromide; PA, palmitic acid; SA, sphinganine; SL, sphingolipids; T2DM, Type 2 Diabetes Mellitus.
References
1. Bertea M, Rütti MF, Othman A, Marti-Jaun J, Hersberger M, von Eckardstein A, et al. Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis (2010) 9:84. doi: 10.1186/1476-511x-9-84
2. Othman A, Rutti MF, Ernst D, Saely CH, Rein P, Drexel H, et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia (2012) 55(2):421–31. doi: 10.1007/s00125-011-2384-1
3. Mwinyi J, Boström A, Fehrer I, Othman A, Waeber G, Marti-Soler H, et al. Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. PloS One (2017) 12(5):175776. doi: 10.1371/journal.pone.0175776
4. Wei N, Pan J, Pop-Busui R, Othman A, Alecu I, Hornemann T, et al. Altered sphingoid base profiles in type 1 compared to type 2 diabetes. Lipids Health Dis (2014) 13(1):161. doi: 10.1186/1476-511X-13-161
5. Zarini S, Perreault L, Newsom SA, Kahn DE, Kerege A, Harrison KA, et al. eoxysphingolipids—Novel Skeletal Muscle Lipids Related to Insulin Resistance in Humans That Decrease Insulin Sensitivity In Vitro. Am Diabetes Assoc (2018). doi: 10.2337/db18-1935-P
6. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol (2010) 688:1–23. doi: 10.1007/978-1-4419-6741-442 1_1
7. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol (2008) 9:139. doi: 10.1038/nrm2329
8. Zuellig RA, Hornemann T, Othman A, Hehl AB, Bode H, Güntert T, et al. Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. Diabetes (2014) 63(4):1326–39. doi: 10.2337/db13-1042
9. Dohrn MF, Othman A, Hirshman SK, Bode H, Alecu I, Fähndrich E, et al. Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy? Eur J Neurol (2015) 22(5):806–14, e55. doi: 10.1111/ene.12663
10. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care (2009) 32(suppl 2):157–63. doi: 10.2337/dc09-S302
11. Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes (2006) 55(6):1813–8. doi: 10.2337/db05-1183
12. Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C, et al. Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care (2005) 28(10):2541–2. doi: 10.2337/diacare.28.10.2541
13. Henriksen T, Wigge L, Nielsen J, Pedersen B, Sandri M, Scheele C, et al. Dysregulated autophagy in muscle precursor cells from humans with type 2 diabetes. Sci Rep (2019) 9(1):1–11. doi: 10.1038/s41598-019-44535-2
14. Teng S, Huang P. The effect of type 2 diabetes mellitus and obesity on muscle progenitor cell function. Stem Cell Res Ther (2019) 10(1):103. doi: 10.1186/s13287-019-1186-0
15. D'Souza DM, Al-Sajee D, Hawke TJ. Diabetic myopathy: impact of diabetes mellitus on skeletal muscle progenitor cells. Front Physiol (2013) 4:379. doi: 10.3389/fphys.2013.00379
16. Vignaud A, Ramond F, Hourde C, Keller A, Butler-Browne G, Ferry A, et al. Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice. Pathobiology (2007) 74(5):291–300. doi: 10.1159/000105812
17. Fiaschi T, Tedesco FS, Giannoni E, Diaz-Manera J, Parri M, Cossu G, et al. Globular adiponectin as a complete mesoangioblast regulator: role in proliferation, survival, motility, and skeletal muscle differentiation. Mol Biol Cell (2010) 21(6):848–59. doi: 10.1091/mbc.e09-04-0310
18. Hommelberg PP, Plat J, Langen R, Schols A, Mensink R. Fatty acid-induced NF-κB activation and insulin resistance in skeletal muscle are chain length dependent. Am J Physiology-Endocrinology Metab (2009) 296(1):E114–E20. doi: 10.1152/ajpendo.00436.2007
19. Yeow K, Cabane C, Turchi L, Ponzio G, Derijard B. Increased MAPK signaling during in vitro muscle wounding. Biochem Biophys Res Commun (2002) 293(1):112–9. doi: 10.1016/S0006-291X(02)00190-0
20. Ko MH, Li CY, Lee CF, Chang CK, Fang SH. Scratch wound closure of myoblasts and myotubes is reduced by inflammatory mediators. Int Wound J (2016) 13(5):680–5. doi: 10.1111/iwj.12346
21. Tanaka S, Ono Y, Sakamoto K. DCEBIO facilitates myogenic differentiation via intermediate conductance Ca2+ activated K+ channel activation in C2C12 myoblasts. J Pharmacol Sci (2017) 133(4):276–9. doi: 10.1016/j.jphs.2017.02.005
22. Fortier M, Comunale F, Kucharczak J, Blangy A, Charrasse S, Gauthier-Rouvière C, et al. RhoE controls myoblast alignment prior fusion through RhoA and ROCK. Cell Death Differ (2008) 15(8):1221–31. doi: 10.1038/cdd.2008.34
23. Sestili P, Barbieri E, Martinelli C, Battistelli M, Guescini M, Vallorani L, et al. Creatine supplementation prevents the inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts. Mol Nutr Food Res (2009) 53(9):1187–204. doi: 10.1002/mnfr.200800504
24. Rodgers BD, Wiedeback BD, Hoversten KE, Jackson MF, Walker RG, Thompson TB, et al. Myostatin stimulates, not inihibits, C2C12 myoblast proliferation. Endocrinology (2014) 155(3):670–5. doi: 10.1210/en.2013-2107
25. Uemura K, Hayashi M, Itsubo T, Oishi A, Iwakawa H, Komatsu M, et al. Myostatin promotes tenogenic differentiation of C2C12 myoblast cells through Smad3. FEBS Open Bio (2017) 7(4):522–32. doi: 10.1002/2211-5463.12200
26. Hirabara SM, Curi R, Maechler P. Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol (2010) 222(1):187–94. doi: 10.1002/jcp.21936
27. Chen X, Xu S, Wei S, Deng Y, Li Y, Yang F, et al. Comparative Proteomic Study of Fatty Acid-treated Myoblasts Reveals Role of Cox-2 in Palmitate-induced Insulin Resistance. Sci Rep (2016) 6(1):21454. doi: 10.1038/srep21454
28. Tong T, Ren N, Soomi P, Wu J, Guo N, Kang H, et al. Theaflavins improve insulin sensitivity through regulating mitochondrial biosynthesis in palmitic acid-induced HepG2 cells. Molecules (2018) 23(12):3382. doi: 10.3390/molecules23123382
29. Kakarla R, Hur J, Kim J, Kim J, Chwae J. Apoptotic cell-derived exosomes: Messages from dying cells. Exp Mol Med (2020), 1–6. doi: 10.1038/s12276-019-0362-8
30. Atlante A, Giannattasio S, Bobba A, Gagliardi S, Petragallo V, Calissano P, et al. An increase in the ATP levels occurs in cerebellar granule cells en route to apoptosis in which ATP derives from both oxidative phosphorylation and anaerobic glycolysis. Biochim Biophys Acta (2005) 1708(1):50–62. doi: 10.1016/j.bbabio.2005.01.009
31. Zhivotosky B, Orrenius S. Assessment of apoptosis and necrosis by DNA fragmentation and morphological criteria. Curr Protoc Cell Biol (2001) 12(1):18. doi: 10.1002/0471143030.cb1803s12
32. Lane JD, Yonekawa T, Thorburn A. Autophagy and cell death. Essays Biochem (2013) 55:105–17. doi: 10.1042/bse0550105
33. Minina EA, Bozhkov PV, Hofius D. Autophagy as initiator or executioner of cell death. Trends Plant Sci (2014) 19(11):692–7. doi: 10.1016/j.tplants.2014.07.007
34. Lauterbach MA, Saavedra V, Mangan MS, Penno A, Thiele C, Latz E, et al. 1-Deoxysphingolipids cause autophagosome and lysosome accumulation and trigger NLRP3 inflammasome activation. Autophagy (2020), 1–15. doi: 10.1080/15548627.2020.1804677
35. McNally EM, Pytel P. Muscle diseases: the muscular dystrophies. Annu Rev Pathol Mech Dis (2007) 2:87–109. doi: 10.1146/annurev.pathol.2.010506.091936
36. Tannu NS, Rao VK, Chaudhary RM, Giorgianni F, Saeed AE, Gao Y, et al. Comparative proteomes of the proliferating C2C12 myoblasts and fully differentiated myotubes reveal the complexity of the skeletal muscle differentiation program. Mol Cell Proteomics (2004) 3(11):1065–82. doi: 10.1074/mcp.M400020-MCP200
37. Aragno M, Mastrocola R, Catalano MG, Brignardello E, Danni O, Boccuzzi G, et al. Oxidative stress impairs skeletal muscle repair in diabetic rats. Diabetes (2004) 53(4):1082–8. doi: 10.2337/diabetes.53.4.1082
38. Nguyen M-H, Cheng M, Koh TJ. Impaired muscle regeneration in ob/ob and db/db mice. Sci World J (2011) 11:1525–35. doi: 10.1100/tsw.2011.137
39. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol (2003) 162(1):303–12. doi: 10.1016/S0002-9440(10)63821-7
40. Capla JM, Grogan RH, Callaghan MJ, Galiano RD, Tepper OM, Ceradini DJ, et al. Diabetes impairs endothelial progenitor cell–mediated blood vessel formation in response to hypoxia. Plast Reconstr Surg (2007) 119(1):59–70. doi: 10.1097/01.prs.0000244830.16906.3f
41. Khan A, Pessin J. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia (2002) 45(11):1475–83. doi: 10.1007/s00125-002-0974-7
42. Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Diabetes (2013), 42–50. doi: 10.1007/978-1-4614-5441-0_6
43. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol (2002) 90(5):11–8. doi: 10.1016/S0002-9149(02)02554-7
44. Bouzakri K, Koistinen HA, Zierath JR. Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes. Curr Diabetes Rev (2005) 1(2):167–74. doi: 10.2174/1573399054022785
45. Alecu I, Othman A, Penno A, Saied EM, Arenz C, von Eckardstein A, et al. Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway. J Lipid Res (2017) 58(1):60–71. doi: 10.1194/jlr.M072421
46. Kramer R, Bielawski J, Kistner-Griffin E, Othman A, Alecu I, Ernst D, et al. Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. FASEB J (2015) 29(11):4461–72. doi: 10.1096/fj.15-272567
47. Othman A, Bianchi R, Alecu I, Wei Y, Porretta-Serapiglia C, Lombardi R, et al. Lowering Plasma 1-Deoxysphingolipids Improves Neuropathy in Diabetic Rats. Diabetes (2015) 64(3):1035–45. doi: 10.2337/db14-1325
48. Penno A, Reilly MM, Houlden H, Laurá M, Rentsch K, Niederkofler V, et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem (2010) 285(15):11178–87. doi: 10.1074/jbc.M109.092973
49. Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, De Rekeneire N, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care (2009) 32(11):1993–7. doi: 10.2337/dc09-0264
50. Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A, et al. Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus. BMJ Open Diabetes Res Care (2015) 3(1):73. doi: 10.1136/bmjdrc-2014-000073
51. Ferrari G, Angelis D, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science (1998) 279(5356):1528–30. doi: 10.1126/science.279.5356.1528
52. Yusuf F, Brand-Saberi B. Myogenesis and muscle regeneration. Histochem Cell Biol (2012) 138(2):187–99. doi: 10.1007/s00418-012-0972-x
53. Nishimura T, Nakamura K, Kishioka Y, Kato-Mori Y, Wakamatsu J-i, Hattori A, et al. Inhibition of matrix metalloproteinases suppresses the migration of skeletal muscle cells. J Muscle Res Cell Motil (2008) 29(1):37–44. doi: 10.1007/s10974-008-9140-2
54. Morgan JE, Partridge TA. Muscle satellite cells. Int J Biochem Cell Biol (2003) 35(8):1151–6. doi: 10.1016/S1357-2725(03)00042-6
55. Le Grand F, Rudnicki MA. Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol (2007) 19(6):628–33. doi: 10.1016/j.ceb.2007.09.012
56. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology (2006) 147(9):4160–8. doi: 10.1210/en.2006-0251
57. Wang X, Yu W, Nawaz A, Guan F, Sun S, Wang C, et al. Palmitate Induced Insulin Resistance by PKCtheta-Dependent Activation of mTOR/S6K Pathway in C2C12 Myotubes. Exp Clin Endocrinol Diabetes (2010) 118(09):657–61. doi: 10.1055/s-0030-1252069
58. Bryner RW, Woodworth-Hobbs ME, Williamson DL, Alway SE. Docosahexaenoic acid protects muscle cells from palmitate-induced atrophy. Int Scholarly Res Notices (2012) 2012:647348–62. doi: 10.5402/2012/647348
59. Yang M, Wei D, Mo C, Zhang J, Wang X, Han X, et al. Saturated fatty acid palmitate-induced insulin resistance is accompanied with myotube loss and the impaired expression of health benefit myokine genes in C2C12 myotubes. Lipids Health Dis (2013) 12(1):1–10. doi: 10.1186/1476-511X-12-104
60. Meex RC, Blaak EE, van Loon LJ. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes Rev (2019) 20(9):1205–17. doi: 10.1111/obr.12862
61. Oh YS, Bae GD, Baek DJ, Park E-Y, Jun H-S. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol (Lausanne) (2018) 9:384. doi: 10.3389/fendo.2018.00384
62. Brøns C, Grunnet LG. Mechanisms in endocrinology: skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes: a causal mechanism or an innocent bystander? Eur J Endocrinol (2017) 176(2):67–78. doi: 10.1530/eje-16-0488
63. Chen R, Hornemann T, Štefanić S, Schraner EM, Zuellig R, Reding T, et al. Serine administration as a novel prophylactic approach to reduce the severity of acute pancreatitis during diabetes in mice. Diabetologia (2020) 63:1885–99. doi: 10.1007/s00125-020-05156-x
64. Becker KA, Uerschels AK, Goins L, Doolen S, McQuerry KJ, Bielawski J, et al. Role of 1-Deoxysphingolipids in docetaxel neurotoxicity. J Neurochem (2020) 154(6):662–72. doi: 10.1111/jnc.14985
65. Alecu I, Tedeschi A, Behler N, Wunderling K, Lamberz C, Lauterbach MR, et al. Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction. J Lipid Res (2017) 58(1):42–59. doi: 10.1194/jlr.M068676
66. Zitomer NC, Mitchell T, Voss KA, Bondy GS, Pruett ST, Garnier-Amblard EC, et al. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem (2009) 284(8):4786–95. doi: 10.1074/jbc.M808798200
67. Wilson ER, Kugathasan U, Abramov AY, Clark AJ, Bennett DL, Reilly MM, et al. Hereditary sensory neuropathy type 1-associated deoxysphingolipids cause neurotoxicity, acute calcium handling abnormalities and mitochondrial dysfunction in vitro. Neurobiol Dis (2018) 117:1–14. doi: 10.1016/j.nbd.2018.05.008
68. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. autophagy (2016) 12(1):1–222. doi: 10.1080/15548627.2020.1797280
69. Xia Q, Huang X, Huang J, Zheng Y, March ME, Li J, et al. The Role of Autophagy in Skeletal Muscle Diseases. Front Physiol (2021) 12:638983(291). doi: 10.3389/fphys.2021.638983
70. Schwartz NU, Mileva I, Gurevich M, Snider J, Hannun YA, Obeid LM, et al. Quantifying 1-deoxydihydroceramides and 1-deoxyceramides in mouse nervous system tissue. Prostaglandins Other Lipid Mediat (2019) 141:40–8. doi: 10.1016/j.prostaglandins.2019.02.005
71. Hannich JT, Loizides-Mangold U, Sinturel F, Harayama T, Vandereycken B, Saini C, et al. Ether lipids, sphingolipids, and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients. Acta Physiologica (2020), 13610. doi: 10.1111/apha.13610
72. Scarlatti F, Bauvy C, Ventruti A, Sala G, Cluzeaud F, Vandewalle A, et al. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem (2004) 279(18):18384–91. doi: 10.1074/jbc.M313561200
73. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3′-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem (2000) 275(2):992–8. doi: 10.1074/jbc.275.2.992
74. Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, et al. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J Biol Chem (2006) 281(13):8518–27. doi: 10.1074/jbc.M506182200
75. Mullen TD, Hannun YA, Obeid LM. Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J (2012) 441(3):789–802. doi: 10.1042/BJ20111626
Keywords: 1-deoxysphingolipids, glucose uptake, myoblasts, myoblast differentiation, autophagy, myotubes, type 2 diabetes mellitus
Citation: Tran D, Myers S, McGowan C, Henstridge D, Eri R, Sonda S and Caruso V (2021) 1-Deoxysphingolipids, Early Predictors of Type 2 Diabetes, Compromise the Functionality of Skeletal Myoblasts. Front. Endocrinol. 12:772925. doi: 10.3389/fendo.2021.772925
Received: 09 September 2021; Accepted: 03 December 2021;
Published: 24 December 2021.
Edited by:
Michele Schiavon, University of Padua, ItalyReviewed by:
Tomohide Takaya, Shinshu University, JapanSean Newsom, Oregon State University, United States
Charles Affourtit, University of Plymouth, United Kingdom
Stephan Krähenbühl, University of Basel, Switzerland
Copyright © 2021 Tran, Myers, McGowan, Henstridge, Eri, Sonda and Caruso. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Vanni Caruso, vanni.caruso@utas.edu.au
†These authors share last authorship